DK3339321T3 - Modulatorer af myc, fremgangsmåder til anvendelse af samme og fremgangsmåder til at identificere stoffer der modulerer myc - Google Patents

Modulatorer af myc, fremgangsmåder til anvendelse af samme og fremgangsmåder til at identificere stoffer der modulerer myc Download PDF

Info

Publication number
DK3339321T3
DK3339321T3 DK18154875.1T DK18154875T DK3339321T3 DK 3339321 T3 DK3339321 T3 DK 3339321T3 DK 18154875 T DK18154875 T DK 18154875T DK 3339321 T3 DK3339321 T3 DK 3339321T3
Authority
DK
Denmark
Prior art keywords
methods
myc
modulars
same
modulate
Prior art date
Application number
DK18154875.1T
Other languages
Danish (da)
English (en)
Inventor
Brian Curtis Turner
Yosef Refaeli
Original Assignee
Taiga Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiga Biotechnologies Inc filed Critical Taiga Biotechnologies Inc
Application granted granted Critical
Publication of DK3339321T3 publication Critical patent/DK3339321T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK18154875.1T 2008-08-28 2009-08-28 Modulatorer af myc, fremgangsmåder til anvendelse af samme og fremgangsmåder til at identificere stoffer der modulerer myc DK3339321T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9270808P 2008-08-28 2008-08-28
EP15175802.6A EP2966084B1 (en) 2008-08-28 2009-08-28 Modulators of myc, methods of using the same and methods of identifying agents that modulate myc

Publications (1)

Publication Number Publication Date
DK3339321T3 true DK3339321T3 (da) 2021-06-21

Family

ID=41722332

Family Applications (3)

Application Number Title Priority Date Filing Date
DK18154875.1T DK3339321T3 (da) 2008-08-28 2009-08-28 Modulatorer af myc, fremgangsmåder til anvendelse af samme og fremgangsmåder til at identificere stoffer der modulerer myc
DK09810692.5T DK2318435T3 (en) 2008-08-28 2009-08-28 Modulators of MYC, methods of using the same, and methods for identifying agents that modulate MYC
DK15175802.6T DK2966084T3 (en) 2008-08-28 2009-08-28 MODULATORS OF MYC, PROCEDURES FOR USING SAME AND PROCEDURES FOR IDENTIFYING SUBSTANCES MODULATING MYC

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK09810692.5T DK2318435T3 (en) 2008-08-28 2009-08-28 Modulators of MYC, methods of using the same, and methods for identifying agents that modulate MYC
DK15175802.6T DK2966084T3 (en) 2008-08-28 2009-08-28 MODULATORS OF MYC, PROCEDURES FOR USING SAME AND PROCEDURES FOR IDENTIFYING SUBSTANCES MODULATING MYC

Country Status (11)

Country Link
US (7) US8784825B2 (cg-RX-API-DMAC7.html)
EP (4) EP2318435B1 (cg-RX-API-DMAC7.html)
JP (5) JP5812861B2 (cg-RX-API-DMAC7.html)
CN (2) CN104353066B (cg-RX-API-DMAC7.html)
AU (1) AU2009285547B2 (cg-RX-API-DMAC7.html)
CA (1) CA2735522C (cg-RX-API-DMAC7.html)
DK (3) DK3339321T3 (cg-RX-API-DMAC7.html)
ES (3) ES2561599T3 (cg-RX-API-DMAC7.html)
IL (6) IL301475A (cg-RX-API-DMAC7.html)
SG (1) SG193831A1 (cg-RX-API-DMAC7.html)
WO (1) WO2010025421A2 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105483088B (zh) 2005-10-18 2021-05-28 国家犹太健康中心 条件无限增殖化长期干细胞和制备和使用所述细胞的方法
US8551968B2 (en) * 2007-03-13 2013-10-08 National Jewish Health Methods for generation of antibodies
CA2723114C (en) 2008-05-16 2018-02-27 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
US9169462B2 (en) 2008-07-21 2015-10-27 Taiga Biotechnologies, Inc. Methods for preparing mature erythrocytes from conditionally immortalized hematopoietic stem cells
ES2561599T3 (es) 2008-08-28 2016-02-29 Taiga Biotechnologies, Inc. Moduladores de MYC, métodos de uso de los mismos, y métodos para identificar agentes que modulan MYC
US20150150975A1 (en) * 2012-07-02 2015-06-04 Sumitomo Dainippon Pharma Co., Ltd. Transdermal cancer antigen peptide preparation
CN114645015A (zh) 2012-07-20 2022-06-21 泰加生物工艺学公司 造血区室的增强的重建和自动重建
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
WO2014142102A1 (ja) 2013-03-12 2014-09-18 大日本住友製薬株式会社 液体水性組成物
WO2016014794A1 (en) 2014-07-25 2016-01-28 Sangamo Biosciences, Inc. Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
CN113699113A (zh) 2014-09-16 2021-11-26 桑格摩治疗股份有限公司 用于造血干细胞中核酸酶介导的基因组工程化和校正的方法和组合物
JP6799683B2 (ja) * 2016-12-02 2020-12-16 タイガ バイオテクノロジーズ，インク． ナノ粒子製剤
US10149898B2 (en) * 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
CA3071448A1 (en) * 2017-08-03 2019-02-07 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of cancer
EP3490584B1 (en) * 2017-08-03 2021-12-08 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
AU2020272664A1 (en) * 2019-04-08 2021-11-04 Taiga Biotechnologies, Inc. Compositions and methods for the cry opreservation of immune cells
US12370217B2 (en) 2019-05-14 2025-07-29 Htyr Acquisition Llc Compositions and methods for treating T cell exhaustion
JP7197538B2 (ja) * 2020-07-03 2022-12-27 タイガ バイオテクノロジーズ，インク． メラノーマの処置のための方法および組成物
EP4469066A1 (en) 2022-01-28 2024-12-04 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies

Family Cites Families (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS62501537A (ja) 1984-12-21 1987-06-25 テクニクロン・リサ−チ・パ−トナ−ズ・ワン リンパ球細胞を電気的に不滅化するための方法
DE3531430A1 (de) 1985-09-03 1987-03-05 Biotest Pharma Gmbh Verfahren zur gewinnung von komponenten aus einer fluessigkeit mit in raeumlich getrennten bereichen vorliegenden komponenten
US4963489A (en) * 1987-04-14 1990-10-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
US4900322A (en) 1986-09-22 1990-02-13 Adams James D Blood component pooling valve and kit
US5476996A (en) * 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5399493A (en) 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5674980A (en) 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
US5849288A (en) * 1990-01-15 1998-12-15 Yeda Research And Development Co. Ltd. Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5851828A (en) 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
IL101147A (en) 1991-03-07 2004-06-20 Gen Hospital Corp Redirection of cellular immunity by receptor chimeras
US6753162B1 (en) 1991-03-07 2004-06-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US5843728A (en) 1991-03-07 1998-12-01 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US5912170A (en) 1991-03-07 1999-06-15 The General Hospital Corporation Redirection of cellular immunity by protein-tyrosine kinase chimeras
US6004811A (en) 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
AU781922B2 (en) 1991-12-17 2005-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5289858A (en) 1991-12-18 1994-03-01 Abbott Laboratories System for accommodating withdrawal of liquid from a bulk supply
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
ATE173016T1 (de) 1992-08-21 1998-11-15 Biogen Inc Von tat abgeleitete transportpolypeptide
US5580760A (en) * 1993-02-22 1996-12-03 The United States Of America As Represented By The Department Of Health And Human Services FUSE binding protein and cDNA therefor
US5824837A (en) * 1993-07-22 1998-10-20 Merck & Co., Inc. Expression of human interleukin-1β in a transgenic animal
US5599705A (en) * 1993-11-16 1997-02-04 Cameron; Robert B. In vitro method for producing differentiated universally compatible mature human blood cells
JPH09510088A (ja) 1994-03-03 1997-10-14 アレクション・ファーマシューティカル・インク 最終補体インヒビター融合遺伝子およびタンパク質
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
CA2241952A1 (en) 1996-01-19 1997-07-24 Allegheny University Of The Health Sciences Cellular immunogens useful as cancer vaccines
US6713247B1 (en) 1996-09-03 2004-03-30 Signal Pharmaceuticials, Inc. Human CNS cell lines and methods of use therefor
AU734827B2 (en) 1997-05-21 2001-06-21 Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
EP0893493A3 (de) * 1997-07-21 2002-12-04 Aventis Pharma Deutschland GmbH Genetisch veränderte Zellen und deren Verwendung in der Prophylaxe oder Therapie von Erkrankungen
CN1206044A (zh) 1997-07-21 1999-01-27 德国赫彻斯特马里奥罗塞尔有限公司 遗传修饰的细胞和它们在预防或治疗疾病中的用途
GB9720585D0 (en) 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
AU1818299A (en) 1997-12-10 1999-06-28 Washington University Anti-pathogen system and methods of use thereof
US6861257B1 (en) 1998-04-08 2005-03-01 Shionogi & Co., Ltd. Methods for isolation of osteoclast precursor cells and inducing their differentiation into osteoclasts
US6835567B1 (en) 1998-04-14 2004-12-28 Signal Pharmaceuticals, Inc. PNS cell lines and methods of use therefor
US6451558B1 (en) * 1998-08-03 2002-09-17 Novartis Ag Genes in the control of hematopoiesis
US6913925B1 (en) 1998-08-12 2005-07-05 Signal Pharmaceuticals Llc Human mesencephalon cell lines and methods of use therefor
AU7497000A (en) 1999-02-28 2000-11-14 Washington University Novel transduction molecules and methods for using same
AU4070500A (en) 1999-04-05 2000-10-23 Biocrystal Limited Assay kits and methods for immune complex-mediated activation involving shed antigens
US6358739B1 (en) 1999-04-12 2002-03-19 Modex Therapeutiques, S.A. Transiently immortalized cells
US6451601B1 (en) 1999-04-12 2002-09-17 Modex Therapeutiques, S.A. Transiently immortalized cells for use in gene therapy
ATE342275T1 (de) 1999-04-12 2006-11-15 Heart Biosystems Gmbh Vorübergehend-immortalisierte zellen zur verwendung in gentherapie
US6308621B1 (en) 1999-06-14 2001-10-30 Heidelberger Druckmaschinen Ag Roller bearing lubrication system and method
US7135287B1 (en) * 1999-10-02 2006-11-14 Biosite, Inc. Human antibodies
US7311920B1 (en) * 1999-10-08 2007-12-25 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
EP1228233B1 (en) 1999-11-10 2007-01-10 Rigel Pharmaceuticals, Inc. Methods and compositions comprising renilla gfp
EP1103615A1 (en) 1999-11-25 2001-05-30 Universite De Geneve Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors
US20010049393A1 (en) * 1999-12-07 2001-12-06 Whitehead Institute For Biomedical Research Methods for defining MYC target genes and uses thereof
AU2001251621A1 (en) 2000-04-12 2001-10-30 Agensys, Inc. Gtp-binding protein useful in treatment and detection of cancer
EP1285577A4 (en) * 2000-05-15 2007-05-09 Sonoko Habu CHIMERIC MOUSE HAVING IMMUNITY CREATED BY USE OF HUMAN CD34 POSITIVE CELLS AND USE THEREOF
US20020155127A1 (en) 2000-06-02 2002-10-24 Danher Wang Genetic vaccine against human immunodeficiency virus
US20030072794A1 (en) * 2000-06-09 2003-04-17 Teni Boulikas Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
US20070248618A1 (en) * 2004-03-16 2007-10-25 Cohen David I Tat-Based vaccine Compositions and Methods of Making and Using Same
EP1326969B1 (en) 2000-09-25 2009-04-15 Genetronics, Inc. Improved system for regulation of transgene expression
WO2002036738A2 (en) 2000-10-30 2002-05-10 Kalobios, Inc. Affinity maturation by competitive selection
US20040241140A1 (en) 2000-11-01 2004-12-02 Pavlakis George N. Expression vectors able to elicit improved immune response and methods of using same
JP3753321B2 (ja) * 2000-12-01 2006-03-08 財団法人実験動物中央研究所 異種細胞の生着、分化および増殖に適したマウスの作出方法、該方法により作出されたマウスならびにそのマウスの用途
WO2002057436A2 (en) 2001-01-19 2002-07-25 Gendel Limited Red blood cell from a transgenic animal as vehicle for polypeptide delivery
JP3454818B1 (ja) 2001-03-16 2003-10-06 直哉 小林 肝臓細胞の増殖方法、該方法により得られる肝臓細胞、およびその用途
GB0117631D0 (en) 2001-07-19 2001-09-12 Syngenta Ltd Improvements in or relating to organic compounds
US7329731B2 (en) 2001-08-31 2008-02-12 Medigene Limited Soluble T cell receptor
CN100506978C (zh) 2001-09-21 2009-07-01 中国人民解放军军事医学科学院野战输血研究所 一种新的造血干/祖细胞的富集方法及其体外定向诱导分化
GB0124391D0 (en) 2001-10-11 2001-11-28 Gene Expression Technologies L Control of gene expression
US20030147887A1 (en) 2001-11-02 2003-08-07 Shen-Wu Wang B-cell lymphoma specific antigen for use in diagnosis and treatment of B-cell malignancies
EP1321034A1 (en) 2001-12-21 2003-06-25 Pfizer Products Inc. Disruption of the phosphodieterase 10 gene
AU2003202908A1 (en) 2002-01-03 2003-07-24 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
AU2003216288B2 (en) 2002-02-13 2009-09-24 Duke University Modulation of immune response by non-peptide binding stress response polypeptides
CN1240439C (zh) * 2002-03-28 2006-02-08 南京凯基生物科技发展有限公司 肿瘤基因开关药物
US7211191B2 (en) 2004-09-30 2007-05-01 Thermogenesis Corp. Blood component separation method and apparatus
EP1499180A4 (en) 2002-04-16 2006-09-13 Dana Farber Cancer Inst Inc CANCER MODELS
GB2387599B (en) 2002-04-17 2005-08-10 Jason Peter Brown Methods for producing antibodies
AU2003228962A1 (en) 2002-05-10 2003-11-11 New Century Pharmaceuticals, Inc. Ferritin fusion proteins for use in vaccines and other applications
JP2006502704A (ja) 2002-05-16 2006-01-26 バヴァリアン・ノルディック・アクティーゼルスカブ Ｈｉｖ調節／アクセサリータンパク質の融合タンパク質
DK1545204T3 (en) 2002-09-06 2016-11-14 The Government Of The Us Secretary Dept Of Health And Human Services Immunotherapy with in vitro selected antigen-specific lymphocytes following non-myeloablative lymphodepletive chemotherapy
CA2501870C (en) 2002-10-09 2013-07-02 Avidex Limited Single chain recombinant t cell receptors
EP1408114B1 (de) * 2002-10-11 2007-01-03 Imvision GmbH Moduläre Antigen-Transporter Moleküle (MAT-Moleküle) zur Modulierung von Immunreaktionen, zugehörige Konstrukte, Verfahren und Verwendungen
AU2003274633A1 (en) 2002-10-15 2004-05-04 Ramot At Tel-Aviv University Ltd. Erythrocyte differentiation factor, gene encoding same, and methods of use thereof
AU2003276403B2 (en) 2002-11-09 2010-04-15 Adaptimmune Limited T cell receptor display
ATE481092T1 (de) 2002-11-27 2010-10-15 Irm Llc Verfahren und zusammensetzungen zur apoptoseinduktion in krebszellen
EP1570061A2 (en) 2002-12-05 2005-09-07 Imperial College Innovations Limited Control of apoptosis using a complex of an oligonucleotide and a regulatory peptide
WO2004071493A1 (en) 2003-02-17 2004-08-26 Peter Burkhard Peptidic nanoparticles as drug delivery and antigen display systems
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
WO2004084805A2 (en) 2003-03-19 2004-10-07 The J. David Gladstone Institutes Acetylated tat polypeptides and methods of use thereof
JP2006524991A (ja) 2003-05-08 2006-11-09 エクサイト セラピーズ インコーポレーティッド 抗原特異的ｔ細胞の作製および単離の方法
WO2005014785A2 (en) 2003-06-18 2005-02-17 The George Washington University Conditionally-immortalized hematopoietic progenitor cell lines
AU2004316996A1 (en) 2003-06-20 2005-09-15 The Regents Of The University Of California Polypeptide transduction and fusogenic peptides
IL161903A0 (en) 2003-07-17 2005-11-20 Gamida Cell Ltd Ex vivo progenitor and stem cell expansion for usein the treatment of disease of endodermally- deri ved organs
KR101284237B1 (ko) 2003-11-19 2013-07-09 수르벡 에이피에스 Ｂｃｌ-2 패밀리에 속한 단백질들, 그들의 단편들 및 암 환자에 대한 그들의 용도
US7705049B2 (en) * 2004-01-21 2010-04-27 New York University Methods for treating non-melanoma cancers with PABA
JP2005232148A (ja) 2004-02-03 2005-09-02 Technion Research & Development Foundation Ltd 神経保護剤としてプロパルギルアミンの使用
AU2005246073B2 (en) 2004-05-19 2010-10-28 Adaptimmune Limited Method of improving T cell receptors
NZ550810A (en) 2004-05-19 2009-05-31 Immunocore Ltd High affinity NY-ESO T cell receptor
ATE475669T1 (de) 2004-06-29 2010-08-15 Immunocore Ltd Einen modifizierten t-zellen-rezeptor exprimierende zellen
US20060068469A1 (en) 2004-08-17 2006-03-30 Research Development Foundation Bacterial vector systems
GB0420963D0 (en) 2004-09-21 2004-10-20 Reneuron Ltd Hepatocyte
US7767453B2 (en) * 2004-10-20 2010-08-03 Whitehead Institute For Biomedical Research Cultured hematopoietic stem cells and method for expansion and analysis thereof
US7527971B2 (en) 2004-10-20 2009-05-05 Vitro Diagnostics, Inc. Adult stem cell lines
US8795650B2 (en) 2004-12-09 2014-08-05 The Regents Of The University Of California Derivation of unlimited quantities of neutrophils or monocyte/dendritic cells
US20060156422A1 (en) * 2005-01-10 2006-07-13 Medical Research Council Methods and compositions for the generation of antibodies
WO2006104978A2 (en) 2005-03-25 2006-10-05 Curagen Corporation Antibodies against the tenascin major antigens
CA2609342A1 (en) 2005-04-26 2006-11-02 Andrei L. Gartel Nucleoside compounds and methods of use thereof
WO2006125962A2 (en) 2005-05-25 2006-11-30 Medigene Limited T cell receptors which specifically bind to vygfvracl-hla-a24
AU2006282799B2 (en) * 2005-08-26 2012-11-29 Healthpartners Research & Education Methods for treatment of headaches by administration of oxytocin
US20070047583A1 (en) 2005-08-29 2007-03-01 Siemens Aktiengesellschaft Method for using a short address in a packet header
CN105483088B (zh) 2005-10-18 2021-05-28 国家犹太健康中心 条件无限增殖化长期干细胞和制备和使用所述细胞的方法
CA2626584A1 (en) * 2005-11-04 2007-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of nav1.8 gene
EP1792627A1 (en) 2005-12-05 2007-06-06 ImVisioN AG Modulation of the immune response by administration of intralymphatic transduction allergen (ITAG-)-molecules
CN101045914A (zh) 2006-03-29 2007-10-03 中国人民解放军军事医学科学院野战输血研究所 体外诱导造血干/祖细胞分化为成熟红细胞的方法与应用
US20080070256A1 (en) 2006-07-26 2008-03-20 National Jewish Medical And Research Center Non-Human Animal Models for B-cell Non-Hodgkin's Lymphoma and Uses Thereof
US8088379B2 (en) 2006-09-26 2012-01-03 The United States Of America As Represented By The Department Of Health And Human Services Modified T cell receptors and related materials and methods
EP2087000A2 (en) 2006-09-29 2009-08-12 Immunocore Ltd. T cell therapies
US8551968B2 (en) 2007-03-13 2013-10-08 National Jewish Health Methods for generation of antibodies
US20110218210A1 (en) 2007-11-02 2011-09-08 Taiga Biotechnologies Compounds for treating abnormal cellular proliferation
WO2009117439A2 (en) 2008-03-17 2009-09-24 The Scripps Research Institute Combined chemical and genetic approaches for generation of induced pluripotent stem cells
KR20210003301A (ko) 2008-05-06 2021-01-11 아스텔라스 인스티튜트 포 리제너러티브 메디슨 다능성 줄기세포로부터 유도된 탈핵 적혈구계 세포를 생산하는 방법
CA2723114C (en) 2008-05-16 2018-02-27 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
EP2304035A2 (en) 2008-06-13 2011-04-06 Life & Brain GmbH Fusion protein and use thereof
US9169462B2 (en) * 2008-07-21 2015-10-27 Taiga Biotechnologies, Inc. Methods for preparing mature erythrocytes from conditionally immortalized hematopoietic stem cells
AU2009274096B2 (en) 2008-07-21 2012-08-02 Becton, Dickinson And Company Density phase separation device
ES2561599T3 (es) 2008-08-28 2016-02-29 Taiga Biotechnologies, Inc. Moduladores de MYC, métodos de uso de los mismos, y métodos para identificar agentes que modulan MYC
PT3031907T (pt) 2008-11-06 2021-01-28 Univ Indiana Res & Tech Corp Materiais e métodos para melhorar procedimentos de enxerto de células estaminais hematopoiéticas
CN102272153B (zh) 2008-11-24 2015-04-15 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 高亲和力t细胞受体及其应用
US9056751B2 (en) 2009-04-14 2015-06-16 Itrec B.V. Hoisting device
WO2011100477A2 (en) 2010-02-10 2011-08-18 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
US20120107317A1 (en) 2010-10-27 2012-05-03 The University Of Hong Kong Use of cytoplasmic c-myc for regulating immune responses
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
TWI575070B (zh) 2011-07-12 2017-03-21 傳斯堅公司 Ｈｂｖ聚合酶突變體
EP3766896B1 (en) 2011-09-15 2025-11-05 The United States of America, as represented by The Secretary, Department of Health and Human Services T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
JP6214004B2 (ja) 2011-09-21 2017-10-25 イッサム リサーチ ディべロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム，リミテッドＹｉｓｓｕｍ Ｒｅｓｅａｒｃｈ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏｍｐａｎｙ Ｏｆ Ｔｈｅ Ｈｅｂｒｅｗ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｊｅｒｕｓａｌｅｍ，Ｌｔｄ． ナノ送達システム
CN104395462B (zh) 2012-05-03 2017-09-26 弗雷德哈钦森癌症研究中心 增强亲和力的t细胞受体及其制备方法
CA2874495A1 (en) 2012-05-23 2013-11-28 The Ohio State University Lipid-coated albumin nanoparticle compositions and methods of making and methods of using the same
DE102012209673A1 (de) 2012-06-08 2013-12-24 Artcline Gmbh Verfahren zum Herstellen einer Leukozytenpräparation und Leukozytenpräparation
CN114645015A (zh) 2012-07-20 2022-06-21 泰加生物工艺学公司 造血区室的增强的重建和自动重建
WO2014018863A1 (en) 2012-07-27 2014-01-30 The Board Of Trustees Of The University Of Illinois Engineering t-cell receptors
US20150209406A1 (en) 2012-09-07 2015-07-30 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells
US20140109246A1 (en) 2012-09-24 2014-04-17 The Regents Of The University Of Colorado, A Body Corporate Methods of generating xenochimaeric mice with tumor and hematopoietic system from the same heterologous species
GB2508414A (en) 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
CA2902448C (en) 2013-03-01 2023-04-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing enriched populations of tumor reactive t cells from peripheral blood
US20160010058A1 (en) 2013-03-01 2016-01-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Methods of producing enriched populations of tumor-reactive t cells from tumor
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
KR20200138445A (ko) 2014-04-24 2020-12-09 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 입양 세포 요법 생성물을 생성하기 위한 유도 만능 줄기 세포의 응용
KR102825102B1 (ko) 2014-12-24 2025-06-26 넥스이뮨, 인크. 면역요법을 위한 나노입자 조성물 및 방법
KR20180081507A (ko) 2015-10-02 2018-07-16 다나-파버 캔서 인스티튜트 인크. 브로모도메인 저해제와 관문 차단의 조합 요법
CN109952313B (zh) 2016-01-15 2023-12-19 伯克利之光生命科技公司 生产患者特异性抗癌治疗剂的方法和其治疗方法
JP6799683B2 (ja) 2016-12-02 2020-12-16 タイガ バイオテクノロジーズ，インク． ナノ粒子製剤
WO2018104909A2 (en) 2016-12-09 2018-06-14 St. Jude Children's Research Hospital Dna methylation profiling for t-cell immunotherapy
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma

Also Published As

Publication number Publication date
EP3339321A1 (en) 2018-06-27
JP2017197567A (ja) 2017-11-02
ES2561599T3 (es) 2016-02-29
WO2010025421A2 (en) 2010-03-04
WO2010025421A3 (en) 2010-08-19
US20100055129A1 (en) 2010-03-04
CA2735522C (en) 2017-04-18
CN102089323B (zh) 2015-01-21
JP6484293B2 (ja) 2019-03-13
IL301475A (en) 2023-05-01
JP6167130B2 (ja) 2017-07-19
JP7208965B2 (ja) 2023-01-19
IL249700A0 (en) 2017-02-28
ES2879225T3 (es) 2021-11-22
IL209968A (en) 2014-11-30
JP2019116481A (ja) 2019-07-18
IL264254B (en) 2020-08-31
CA2735522A1 (en) 2010-03-04
DK2966084T3 (en) 2018-08-06
HK1159643A1 (zh) 2012-08-03
US20140356392A1 (en) 2014-12-04
US9775897B2 (en) 2017-10-03
US12496341B2 (en) 2025-12-16
JP6817353B2 (ja) 2021-01-20
EP2966084A1 (en) 2016-01-13
US20240156957A1 (en) 2024-05-16
EP3339321B1 (en) 2021-04-28
DK2318435T3 (en) 2016-02-29
IL209968A0 (en) 2011-02-28
AU2009285547A1 (en) 2010-03-04
EP2966084B1 (en) 2018-04-25
JP2021073184A (ja) 2021-05-13
US20130177586A1 (en) 2013-07-11
IL249700B (en) 2019-02-28
IL232432A (en) 2017-01-31
US20220362377A1 (en) 2022-11-17
CN102089323A (zh) 2011-06-08
CN104353066A (zh) 2015-02-18
US20200215188A1 (en) 2020-07-09
IL276146B1 (en) 2023-04-01
IL276146B2 (en) 2023-08-01
IL232432A0 (en) 2014-06-30
JP2015147789A (ja) 2015-08-20
US10556006B2 (en) 2020-02-11
US20180092972A1 (en) 2018-04-05
IL264254A (en) 2019-02-28
US8784825B2 (en) 2014-07-22
SG193831A1 (en) 2013-10-30
EP2318435A2 (en) 2011-05-11
US11369678B2 (en) 2022-06-28
EP2318435A4 (en) 2011-08-10
CN104353066B (zh) 2017-05-10
EP2318435B1 (en) 2015-12-23
JP5812861B2 (ja) 2015-11-17
HK1257269A1 (en) 2019-10-18
EP3916010A1 (en) 2021-12-01
US8828723B2 (en) 2014-09-09
AU2009285547B2 (en) 2012-05-31
IL276146A (en) 2020-09-30
HK1219491A1 (en) 2017-04-07
ES2681478T3 (es) 2018-09-13
JP2012501347A (ja) 2012-01-19

Similar Documents

Publication Publication Date Title
DK3339321T3 (da) Modulatorer af myc, fremgangsmåder til anvendelse af samme og fremgangsmåder til at identificere stoffer der modulerer myc
BRPI0922039A2 (pt) método e equipamento para vedação.
DK2270818T3 (da) Polyelektrolyt og fremgangsmåde til fremstilling af polyelektrolytten
DK2518655T3 (da) Anordning og fremgangsmåde til forebyggelse af hypoglykæmi
BRPI0913227A2 (pt) método, e objeto
DK2376519T3 (da) TGR5-modulatorer og fremgangsmåde til anvendelse deraf
DK2300808T3 (da) Systemer og fremgangsmåder til billeddannelse ved anvendelse af absorption
BRPI0919575A2 (pt) método, e, composição
DK3081315T3 (da) Fremgangsmåde og system til sortering af fødevarer
DK3222615T3 (da) Psma-bindende stoffer og anvendelser deraf
BRPI0920406A2 (pt) dispositivos de terminação e métodos relacionados.
BRPI0809573A8 (pt) composição, e, método
BRPI0807755A2 (pt) Sementes revestidas e métodos para fabricação de sementes revestidas.
FI20075978A0 (fi) Järjestely ja menetelmä
BRPI0910723A2 (pt) aparelho e método de frenagem.
DK2188336T3 (da) Sammensætning omfattende et eller flere hydrofobt modificerede polyacrylamider og fremgangsmåde til anvendelse af sammensætningen
BRPI0814467A2 (pt) Método, e, biocombustível
BRPI0823277A2 (pt) Composição, e , método
NO20082795L (no) Blandeapparat og framgangsmate ved bruk av samme
DK2252312T3 (da) Fremgangsmåder til forebyggelse eller behandling af insulinresistens
DK2222314T3 (da) Anvendelser og midler til opnåelse af bronchorelaxation
DK3130367T3 (da) System til vurdering af insulinfølsomhed
DK2195548T3 (da) Leje, og fremgangsmåde og håndtering af lejet
BRPI0814167A2 (pt) Composição, e, método
DK2217376T3 (da) Kuvette og fremgangsmåde til anvendelse af denne kuvette